The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13.
 
Kwai Han Yoo
No Relationships to Disclose
 
Jinhyun Cho
No Relationships to Disclose
 
Ki Hyeong Lee
No Relationships to Disclose
 
Keon Uk Park
No Relationships to Disclose
 
Ki Hwan Kim
No Relationships to Disclose
 
Eun Kyung Cho
No Relationships to Disclose
 
Kyung A. Kwon
No Relationships to Disclose
 
Heuijune Ahn
No Relationships to Disclose
 
HyeRyun Kim
No Relationships to Disclose
 
Hoon-Gu Kim
No Relationships to Disclose
 
Ha Yeon Lee
No Relationships to Disclose
 
Hwan Jung Yun
No Relationships to Disclose
 
Jin-Hyoung Kang
No Relationships to Disclose
 
Jaeheon Jeong
No Relationships to Disclose
 
Moon Young Choi
No Relationships to Disclose
 
Sin-Ho Jung
No Relationships to Disclose
 
Jong-Mu Sun
No Relationships to Disclose
 
Jin Seok Ahn
No Relationships to Disclose
 
Keunchil Park
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Hanmi; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca
 
Myung-Ju Ahn
No Relationships to Disclose